Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284387 · ClinicalTrials.gov registry record · Phase 2
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT01284387: Completed Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT01284387 is a Phase 2 study that has completed, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 126 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01284387, a Phase 2 study, has completed, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
A Phase II clinical research study to evaluate the efficacy and safety of two different dose levels of an injectable investigational treatment (ACC-001) in subjects with Mild-to-Moderate Alzheimer's disease. ACC-001 (vanutide cridificar) is a beta amyloid fragment attached to a carrier protein. It is intended to help induce an antibody response against beta amyloid and is administered as an intramuscular injection.
Interventions
- BIOLOGICAL ACC-001 (vanutide cridificar)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT01284387 record still lists
NCT01284387 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which ACC-001 (vanutide cridificar) is the first listed.
NCT01284387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01284387 about?
NCT01284387 is a clinical study titled "Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease". A Phase II clinical research study to evaluate the efficacy and safety of two different dose levels of an injectable investigational treatment (ACC-001) in subjects with Mild-to-Moderate Alzheimer's disease. ACC-001 (vanutide cridificar) is a beta amyloid fragment attached to a carrier protein. It i...
What is the current status of trial NCT01284387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2011-01. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01284387?
The interventions under investigation include: ACC-001 (vanutide cridificar) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01284387?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01284387's enrollment target sits among peer trials
126 556th of 2000 higher than 1,443 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia